These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30710068)

  • 1. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
    Colomer R; Saura C; Sánchez-Rovira P; Pascual T; Rubio IT; Burgués O; Marcos L; Rodríguez CA; Martín M; Lluch A
    Oncologist; 2019 May; 24(5):603-611. PubMed ID: 30710068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
    Man VC; Cheung PS
    Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for early breast cancer.
    Mieog JS; van de Velde CJ
    Expert Opin Pharmacother; 2009 Jun; 10(9):1423-34. PubMed ID: 19505212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
    Wang-Lopez Q; Chalabi N; Abrial C; Radosevic-Robin N; Durando X; Mouret-Reynier MA; Benmammar KE; Kullab S; Bahadoor M; Chollet P; Penault-Llorca F; Nabholtz JM
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):88-104. PubMed ID: 25900915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
    Ma X; Wang X; Huang J; Chen Y; Zhang J; Zhang B; Shi C; Liu L
    PLoS One; 2016; 11(8):e0160148. PubMed ID: 27579484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of neoadjuvant therapy for breast cancer.
    Haddad TC; Goetz MP
    Ann Surg Oncol; 2015 May; 22(5):1408-15. PubMed ID: 25727557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.
    Cain H; Macpherson IR; Beresford M; Pinder SE; Pong J; Dixon JM
    Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):642-652. PubMed ID: 28669449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
    Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
    Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.